The PrECOG0105 phase 2 trial showed that the LOH test identified patients with triple-negative breast cancer with a high LOH (≥10%) score, and lacking BRCA1/2 mutation, who achieved a favorable pathologic response to iniparib in combination with chemotherapy. Here, BRCA1 is linked to triple-negative breast carcinoma.